Facebook Slap Shows FDA Has Eagle Eye On Social Media

Law360, New York (March 13, 2014, 6:22 PM EDT) -- The U.S. Food and Drug Administration’s unusual criticism this week of a drugmaker's Facebook activities offered precious little insight into how regulators will police pharmaceutical promotion on social media, but it’s a fresh reminder that every digital move is being scrutinized, experts say.

In its so-called untitled letter, the FDA took aim at a bare-bones Facebook profile that included a logo for hypothyroid medicine Tirosint and, without disclosing possible side effects, advised potential customers to talk to their doctor about it. While no potential benefits were...
To view the full article, register now.